Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:EARSNASDAQ:GELSNASDAQ:MENASDAQ:PRPH On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeEARSAuris Medical$0.30$2.88$0.73▼$6.60$3.43M1.173.10 million shs830,271 shsGELSGelteq$1.91+13.7%$1.34$0.77▼$5.50$18.03MN/A1.15 million shs261,658 shsME23andMe$0.50-35.3%$0.73$0.53▼$12.32$13.36M1.191.29 million shs29.28 million shsPRPHProPhase Labs$0.39-2.0%$0.35$0.22▼$5.45$16.21M-0.472.71 million shs3.38 million shs2025 Gold Forecast: A Perfect Storm for DemandUnlock the timeless value of gold with our exclusive 2025 Gold Forecasting Report. Explore why gold remains the ultimate investment for safeguarding wealth against inflation, economic shifts, and global uncertainties. Whether you're planning for future generations or seeking a reliable asset in turbulent times, this report is your essential guide to making informed decisions.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceEARSAuris Medical0.00%0.00%0.00%0.00%-80.39%GELSGelteq+13.69%+34.51%+118.51%-9.48%+190,999,900.00%ME23andMe0.00%0.00%0.00%-80.47%-95.74%PRPHProPhase Labs-1.98%+27.72%+38.02%+19.08%-92.47%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationEARSAuris MedicalN/AN/AN/AN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/AN/AN/AN/APRPHProPhase Labs1.5664 of 5 stars0.05.00.00.01.51.71.3Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceEARSAuris Medical 0.00N/AN/AN/AGELSGelteq 0.00N/AN/AN/AME23andMe 1.00SellN/AN/APRPHProPhase Labs 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest EARS, PRPH, GELS, and ME Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails3/22/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)3/7/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)2/19/2025ME23andMeWeiss RatingsSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingSell (E+) ➝ Sell (E+)(Data available from 5/17/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookEARSAuris MedicalN/AN/AN/AN/A$1.57 per shareN/AGELSGelteqN/AN/AN/AN/AN/AN/AME23andMe$208.78M0.06$0.54 per share0.93$2.34 per share0.21PRPHProPhase Labs$6.77M2.39N/AN/A$2.74 per share0.14Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateEARSAuris Medical-$8.75MN/A0.00∞N/AN/AN/AN/AN/AGELSGelteqN/AN/A0.00∞N/AN/AN/AN/AN/AME23andMe-$666.70M-$15.45N/A∞N/A-183.39%-170.07%-62.13%N/APRPHProPhase Labs-$16.78M-$1.26N/AN/AN/A-217.64%-62.92%-30.22%5/20/2025 (Estimated)Latest EARS, PRPH, GELS, and ME EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/20/2025Q1 2025PRPHProPhase Labs-$0.18N/AN/AN/A$2.45 millionN/ACompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthEARSAuris MedicalN/AN/AN/AN/AN/AGELSGelteqN/AN/AN/AN/AN/AME23andMeN/AN/AN/AN/AN/APRPHProPhase LabsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioEARSAuris MedicalN/A3.833.83GELSGelteqN/AN/AN/AME23andMeN/A1.050.91PRPHProPhase Labs0.481.471.33Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipEARSAuris Medical6.03%GELSGelteqN/AME23andMe36.10%PRPHProPhase Labs9.45%Insider OwnershipCompanyInsider OwnershipEARSAuris MedicalN/AGELSGelteqN/AME23andMe26.32%PRPHProPhase Labs20.70%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableEARSAuris Medical132,20011.42 millionN/ANot OptionableGELSGelteqN/A9.44 millionN/AN/AME23andMe77026.83 million19.77 millionNot OptionablePRPHProPhase Labs13041.88 million18.93 millionOptionableEARS, PRPH, GELS, and ME HeadlinesRecent News About These CompaniesProPhase Labs Delays Form 10-Q FilingMay 16 at 6:55 PM | tipranks.comProPhase Labs Inc. to Present First Quarter 2025 Financial Results on May 20, 2025May 13, 2025 | globenewswire.comCovid Test Lab Weighs Unusual Debt-Collection Plan: BankruptcyMay 13, 2025 | wsj.comProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024April 2, 2025 | seekingalpha.comProPhase Labs reports FY24 EPS ($2.61) vs (98c) last yearApril 1, 2025 | markets.businessinsider.comProPhase Labs, Inc. (NASDAQ:PRPH) Q4 2024 Earnings Call TranscriptApril 1, 2025 | msn.comProPhase Labs, Inc. (PRPH) Q4 2024 Earnings Call TranscriptMarch 31, 2025 | seekingalpha.comProPhase Labs, Inc. Announces Financial Results for the Year Ended December 31, 2024March 31, 2025 | globenewswire.comProPhase Labs FY 2024 Earnings PreviewMarch 28, 2025 | msn.com6PRPH : An Overview of ProPhase Labs's EarningsMarch 28, 2025 | benzinga.comProPhase Labs Inc. to Present 2024 Year End Financial Results on March 31, 2025March 27, 2025 | globenewswire.comProPhase Labs, Inc. CEO Ted Karkus to Present at Q1 Investor Summit Virtual on March 11thMarch 7, 2025 | quiverquant.comProPhase Labs to Present at the Investor Summit Virtual on March 11March 7, 2025 | globenewswire.comBears are Losing Control Over ProPhase Labs (PRPH), Here's Why It's a 'Buy' NowMarch 5, 2025 | zacks.comDiamond Equity Research Releases Update Note on ProPhase Labs Inc. (NASDAQ: PRPH)February 26, 2025 | globenewswire.comProPhase Labs examines opportunities to leverage DTC multi-media infrastructureFebruary 25, 2025 | markets.businessinsider.comProPhase Labs Examines Strategic Opportunities to Leverage Its DTC Multi-Media Infrastructure with Telehealth Physician Networks for Prescription DrugsFebruary 25, 2025 | globenewswire.comProPhase Labs provides update on cash generation initiativesFebruary 20, 2025 | markets.businessinsider.comProPhase Labs Announces Excellent Progress with Crown Medical Collections Targeting Over $50 Million in Net Near-Term Cash Recovery from COVID-19 ReceivablesFebruary 20, 2025 | globenewswire.comProPhase Labs hires former Barstool Sports COO Stuart Hollenshead, plans cost-cutting measuresFebruary 19, 2025 | msn.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesIf the U.S.-China Trade Reset Holds, These 3 Stocks Could FlyBy Chris Markoch | May 16, 2025View If the U.S.-China Trade Reset Holds, These 3 Stocks Could FlyWhy Institutions Are Buying Super Micro Computer Stock AgainBy Gabriel Osorio-Mazilli | April 28, 2025View Why Institutions Are Buying Super Micro Computer Stock AgainMicrosoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock WinsBy Chris Markoch | May 15, 2025View Microsoft and OpenAI Just Hit Reset—Here’s Why MSFT Stock WinsAMD’s AI-Powered Stock Price Rally Just Shifted GearsBy Thomas Hughes | May 14, 2025View AMD’s AI-Powered Stock Price Rally Just Shifted Gears3 Stocks to Watch as Bitcoin Nears $100k AgainBy Gabriel Osorio-Mazilli | May 5, 2025View 3 Stocks to Watch as Bitcoin Nears $100k AgainEARS, PRPH, GELS, and ME Company DescriptionsAuris Medical NASDAQ:EARSAuris Medical Holding Ltd. engages in the development of novel products that address unmet medical needs in neurology and central nervous system disorders. It operates through Switzerland and Australia geographical segments. Its product pipeline includes AM-125, AM-201, AM301, Sonsuvi, and Keyzilen. The company was founded by Thomas Meyer in April 2003 and is headquartered in Hamilton, Bermuda.Gelteq NASDAQ:GELS$1.91 +0.23 (+13.69%) As of 05/16/2025 04:00 PM EasternGelteq Inc. is a biotechnology company which specializes in the formulation, development and manufacturing of ingestible gel platform designed for nutrient and drug delivery. The Company is focused on advancing and commercializing its delivery solutions within core verticals pharmaceuticals, over-the-counter medications, nutraceuticals, animal medications and sports nutrition. Gelteq Inc. is based in NEW YORK.23andMe NASDAQ:ME$0.50 -0.27 (-35.32%) Closing price 03/28/2025Extended Trading$0.50 0.00 (0.00%) As of 03/28/2025 08:00 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.23andMe Holding Co. operates as a consumer genetics testing company. The company operates in two segments, Consumer & Research Services and Therapeutics. The Consumer & Research Services segment provides a suite of genetic reports, including information on customers' genetic ancestral origins, personal genetic health risks, and chances of passing on certain rare carrier conditions to their children, as well as reports on how genetics can impact responses to medications. This segments also operates Lemonaid telehealth platform to access affiliated licensed healthcare professionals for medical consultation and treatment for various common conditions; and offers research services. The Therapeutics segment focuses on the drug development; and discovery and development of novel therapies to enhance patient lives across various therapeutic areas, including oncology, respiratory, and cardiovascular diseases, as well as offers out-licensing intellectual property associated with identified drug targets related to drug candidates under clinical development. The company's therapeutics product portfolio comprises 23ME-00610 (P006), a humanized monoclonal antibody, which is in phase 1/2a clinical trials to interfere with the ability of CD200R1 to interact with CD200 in cancer cells; and GSK6097608, an antibody that targets CD96 for attenuating T and NK cell anti-tumor immune responses. The company was incorporated in 2006 and is headquartered in South San Francisco, California.ProPhase Labs NASDAQ:PRPH$0.39 -0.01 (-1.98%) Closing price 05/16/2025 04:00 PM EasternExtended Trading$0.39 +0.00 (+0.52%) As of 05/16/2025 07:59 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.ProPhase Labs, Inc. develops and commercializes novel drugs, dietary supplements, and compounds in the United States. It operates through two segments: Diagnostic Services and Consumer Products. The company provides a range of TK supplements, including Legendz XL for male sexual health; and Triple Edge XL, an energy and stamina booster. It offers contract manufacturing services, such as product development, pre-commercialization, production, warehousing, and distribution; COVID-19 diagnostic information services to a range of customers, including health plans, third party payers, and government organizations; and respiratory pathogen panel molecular testing services, as well as personal genomics products and services. In addition, the company involved in the research, development, manufacture, distribution, marketing, and sale of over the counter (OTC) consumer healthcare products and dietary supplements; and retail operations. The company was formerly known as The Quigley Corporation. ProPhase Labs, Inc. was founded in 1989 and is headquartered in Garden City, New York. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas MarketBeat Week in Review – 05/12 - 05/16 Retail Investors Are Betting Big on Rocket Lab—Should You Too? Meta's 5 Key Pillars for AI Growth—Zuckerberg's Bold Vision Taiwan Semiconductor Stock Is The Gift That Keeps on Giving GE Aerospace: Qatar Deal Fuels Multi-Billion Dollar Growth Engine Alibaba's Earnings Just Changed Everything for the Stock Plug Power: Is Q1 Noise An Opportunity for Accumulation? Cisco Stock Eyes New Highs in 2025 on AI, Earnings, Upgrades Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
